William Blair Issues Optimistic Forecast for DVAX Earnings

Dynavax Technologies Corporation (NASDAQ:DVAX) – Equities research analysts at William Blair increased their Q1 2026 EPS estimates for Dynavax Technologies in a research note issued to investors on Thursday, November 6th. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings per share of $0.14 for the quarter, up from their previous estimate of $0.11. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.32 per share. William Blair also issued estimates for Dynavax Technologies’ Q2 2026 earnings at $0.19 EPS, Q4 2026 earnings at $0.07 EPS and FY2026 earnings at $0.60 EPS.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.07. The firm had revenue of $94.88 million for the quarter, compared to analysts’ expectations of $94.00 million. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%.

DVAX has been the subject of a number of other reports. Weiss Ratings restated a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, October 8th. JMP Securities reissued a “market outperform” rating and issued a $32.00 price objective on shares of Dynavax Technologies in a report on Friday, August 22nd. Finally, Wall Street Zen raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $24.33.

Dynavax Technologies Stock Down 1.5%

Dynavax Technologies stock opened at $10.83 on Friday. Dynavax Technologies has a one year low of $9.20 and a one year high of $14.63. The stock has a fifty day moving average of $10.02 and a 200 day moving average of $10.29. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.01 and a current ratio of 6.65. The stock has a market cap of $1.27 billion, a PE ratio of -23.54 and a beta of 1.09.

Insider Activity

In other Dynavax Technologies news, Director Scott Dunseth Myers bought 3,800 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was purchased at an average price of $10.82 per share, for a total transaction of $41,116.00. Following the completion of the transaction, the director owned 35,004 shares of the company’s stock, valued at $378,743.28. This trade represents a 12.18% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 2.98% of the company’s stock.

Institutional Investors Weigh In On Dynavax Technologies

Several institutional investors and hedge funds have recently modified their holdings of DVAX. DekaBank Deutsche Girozentrale purchased a new position in shares of Dynavax Technologies in the first quarter worth $30,000. Caitong International Asset Management Co. Ltd increased its holdings in Dynavax Technologies by 5,485.7% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 2,304 shares during the last quarter. Hantz Financial Services Inc. lifted its stake in Dynavax Technologies by 236.9% in the 3rd quarter. Hantz Financial Services Inc. now owns 3,854 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 2,710 shares in the last quarter. LSV Asset Management purchased a new stake in Dynavax Technologies in the 3rd quarter worth $89,000. Finally, Osaic Holdings Inc. boosted its holdings in shares of Dynavax Technologies by 15.1% during the 2nd quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 1,226 shares during the last quarter. Institutional investors own 96.96% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.